Viridian Therapeutics, Inc. Common Stock VRDN
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T00:49:01.171Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:01:51.090163464Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T00:49:00.531981+00:00
Viridian Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | 29.59 | 148.6% | 10.7% | |||
| 45Δ | 31.38 | 81.2% | 6.7% | 30.41 | 131.0% | 8.4% |
| 50Δ | 30.78 | 76.9% | 5.3% | 31.11 | 119.5% | 6.6% |
| 55Δ | 30.31 | 82.9% | 4.9% | 31.68 | 109.6% | 5.3% |
| 60Δ | 29.79 | 88.6% | 4.4% | |||
| 65Δ | 29.19 | 93.7% | 3.9% | |||
| 70Δ | 28.66 | 91.9% | 3.1% | |||
| 75Δ | 28.16 | 86.8% | 2.3% | |||
| 80Δ | 27.32 | 92.8% | 1.8% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 29.59
- IV
- 148.6%
- B/E move
- 10.7%
45Δ
- Pseudo strike
- 31.38
- IV
- 81.2%
- B/E move
- 6.7%
- Pseudo strike
- 30.41
- IV
- 131.0%
- B/E move
- 8.4%
50Δ
- Pseudo strike
- 30.78
- IV
- 76.9%
- B/E move
- 5.3%
- Pseudo strike
- 31.11
- IV
- 119.5%
- B/E move
- 6.6%
55Δ
- Pseudo strike
- 30.31
- IV
- 82.9%
- B/E move
- 4.9%
- Pseudo strike
- 31.68
- IV
- 109.6%
- B/E move
- 5.3%
60Δ
- Pseudo strike
- 29.79
- IV
- 88.6%
- B/E move
- 4.4%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 29.19
- IV
- 93.7%
- B/E move
- 3.9%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 28.66
- IV
- 91.9%
- B/E move
- 3.1%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 28.16
- IV
- 86.8%
- B/E move
- 2.3%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 27.32
- IV
- 92.8%
- B/E move
- 1.8%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 72.54% | |
| 73.00% | |
| 66.84% | |
| 71.58% | |
| 76.17% | |
| 74.22% | |
| 71.05% | |
| 74.44% | |
| 73.48% | |
| 73.34% |
Biotechnology
VRTX
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
More →VSTM
Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients. The company is headquartered in…
More →VYGR
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, is focused on developing treatments for patients with severe neurological diseases. The company is headquartered…
More →WHWK
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. The company is headquartered in…
More →WVE
Description unavailable
More →XBIT
Description unavailable
More →